FILING ANALYSIS · TUESDAY, NOVEMBER 10
Corbus Pharmaceuticals Holdings, Inc. CRBP — 8-K: Results of Operations and Financial Condition
neutral
Corbus Pharmaceuticals reported positive topline data from the CANYON-1 Phase 1b study of CRB-913 in obesity, demonstrating a mean weight loss of 5% after 12 weeks at 60 mg daily dose with no plateau observed and favorable safety and tolerability, and also initiated dosing in the TEMPO-1 registrational study of sutantatug envedotin in patients with 2L+ oropharyngeal cancer
The filing
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →